Xvivo Perfusion Ab Stock Performance
| XVIPF Stock | USD 20.70 0.59 2.93% |
Xvivo Perfusion has a performance score of 4 on a scale of 0 to 100. The firm maintains a market beta of 0.92, which attests to possible diversification benefits within a given portfolio. Xvivo Perfusion returns are very sensitive to returns on the market. As the market goes up or down, Xvivo Perfusion is expected to follow. Xvivo Perfusion AB right now maintains a risk of 2.87%. Please check out Xvivo Perfusion AB information ratio, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Xvivo Perfusion AB will be following its historical returns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Xvivo Perfusion AB are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Xvivo Perfusion may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
| Begin Period Cash Flow | 354.2 M | |
| Total Cashflows From Investing Activities | -187.7 M |
Xvivo |
Xvivo Perfusion Relative Risk vs. Return Landscape
If you would invest 1,905 in Xvivo Perfusion AB on September 30, 2025 and sell it today you would earn a total of 165.00 from holding Xvivo Perfusion AB or generate 8.66% return on investment over 90 days. Xvivo Perfusion AB is currently producing 0.1696% returns and takes up 2.8706% volatility of returns over 90 trading days. Put another way, 25% of traded pink sheets are less volatile than Xvivo, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Xvivo Perfusion Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xvivo Perfusion's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Xvivo Perfusion AB, and traders can use it to determine the average amount a Xvivo Perfusion's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0591
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | XVIPF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Xvivo Perfusion is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xvivo Perfusion by adding it to a well-diversified portfolio.
Xvivo Perfusion Fundamentals Growth
Xvivo Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Xvivo Perfusion, and Xvivo Perfusion fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xvivo Pink Sheet performance.
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Current Valuation | 536.1 M | |||
| Shares Outstanding | 29.83 M | |||
| Price To Earning | 166.11 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 16.90 X | |||
| Revenue | 258.39 M | |||
| EBITDA | 39.2 M | |||
| Cash And Equivalents | 22.66 M | |||
| Cash Per Share | 0.86 X | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 2.28 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Earnings Per Share | 0.10 X | |||
| Total Asset | 1.54 B | |||
About Xvivo Perfusion Performance
By analyzing Xvivo Perfusion's fundamental ratios, stakeholders can gain valuable insights into Xvivo Perfusion's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Xvivo Perfusion has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Xvivo Perfusion has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 115 people.Things to note about Xvivo Perfusion AB performance evaluation
Checking the ongoing alerts about Xvivo Perfusion for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Xvivo Perfusion AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xvivo Perfusion AB has accumulated about 22.66 M in cash with (12.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Roughly 12.0% of the company outstanding shares are owned by insiders |
- Analyzing Xvivo Perfusion's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xvivo Perfusion's stock is overvalued or undervalued compared to its peers.
- Examining Xvivo Perfusion's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xvivo Perfusion's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xvivo Perfusion's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xvivo Perfusion's pink sheet. These opinions can provide insight into Xvivo Perfusion's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Xvivo Pink Sheet analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |